5CAL

EGFR kinase domain mutant "TMLR" with compound 24

Summary for 5CAL

Entry DOI	10.2210/pdb5cal/pdb
Descriptor	Epidermal growth factor receptor, 2,2-dimethyl-3-[(4-{[2-methyl-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-yl]amino}pyrimidin-2-yl)amino]propanamide (2 entities in total)
Functional Keywords	protein kinase inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Homo sapiens (Human)
Cellular location	Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted: P00533
Total number of polymer chains	1
Total formula weight	37931.86
Authors	Eigenbrot, C.,Yu, C. (deposition date: 2015-06-29, release date: 2015-10-28, Last modification date: 2024-03-06)
Primary citation	Heald, R.,Bowman, K.K.,Bryan, M.C.,Burdick, D.,Chan, B.,Chan, E.,Chen, Y.,Clausen, S.,Dominguez-Fernandez, B.,Eigenbrot, C.,Elliott, R.,Hanan, E.J.,Jackson, P.,Knight, J.,La, H.,Lainchbury, M.,Malek, S.,Mann, S.,Merchant, M.,Mortara, K.,Purkey, H.,Schaefer, G.,Schmidt, S.,Seward, E.,Sideris, S.,Shao, L.,Wang, S.,Yeap, K.,Yen, I.,Yu, C.,Heffron, T.P. Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J.Med.Chem., 58:8877-8895, 2015 Cited by PubMed: 26455919 DOI: 10.1021/acs.jmedchem.5b01412 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.7 Å)

Structure validation